89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focusing on liver and cardiometabolic diseases, has announced an inducement grant approved by its Compensation Committee. The grant includes non-qualified stock options to purchase 15,000 shares of the company's common stock, awarded to one new employee on September 13, 2024.
The grant, made under the company's 2023 Inducement Plan, complies with Nasdaq Listing Rule 5635(c)(4). The exercise price equals the closing price of 89bio's common stock on the grant date. The options will vest over four years, with 25% vesting after one year and the remainder vesting in 12 equal quarterly installments, contingent on continued employment.
89bio, Inc. (Nasdaq: ETNB), un'azienda biofarmaceutica in fase clinica focalizzata sulle malattie epatiche e cardiometaboliche, ha annunciato un'incentivo approvato dal suo Comitato di Compensazione. L'incentivo comprende opzioni su azioni non qualificate per l'acquisto di 15.000 azioni del comune stock dell'azienda, assegnate a un nuovo dipendente il 13 settembre 2024.
L'incentivo, effettuato nell'ambito del Piano di Incentivo 2023 dell'azienda, è conforme alla Regola di Quotazione 5635(c)(4) di Nasdaq. Il prezzo di esercizio è pari al prezzo di chiusura delle azioni ordinarie di 89bio nel giorno dell'assegnazione. Le opzioni vesteranno in quattro anni, con il 25% che vesterà dopo un anno e il resto in 12 rate trimestrali uguali, a condizione del proseguimento dell'impiego.
89bio, Inc. (Nasdaq: ETNB), una compañía biofarmacéutica en etapa clínica centrada en enfermedades hepáticas y cardiometabólicas, ha anunciado una concesión de incentivos aprobada por su Comité de Compensación. La concesión incluye opciones sobre acciones no calificadas para comprar 15,000 acciones del capital social de la empresa, otorgadas a un nuevo empleado el 13 de septiembre de 2024.
La concesión, realizada bajo el Plan de Incentivos 2023 de la compañía, cumple con la Regla de Cotización 5635(c)(4) de Nasdaq. El precio de ejercicio es igual al precio de cierre de las acciones ordinarias de 89bio en la fecha de concesión. Las opciones se devengarán en cuatro años, con el 25% devengándose después de un año y el restante en 12 pagos trimestrales iguales, condicionado a la continuidad del empleo.
89bio, Inc. (Nasdaq: ETNB), 간 질환 및 심대사 질환에 초점을 맞춘 임상 단계의 생명공학 회사가 보상 위원회에 의해 승인된 유인 부여를 발표했습니다. 이 부여에는 15,000주를 구매할 수 있는 비자격 주식 옵션이 포함되며, 2024년 9월 13일에 한 새 직원에게 수여됩니다.
이 부여는 회사의 2023 유인 계획에 따라 이루어지며, Nasdaq 상장 규칙 5635(c)(4)을 준수합니다. 행사 가격은 부여 당일 89bio의 보통 주식 종가와 같습니다. 옵션은 4년에 걸쳐 발생됩니다, 1년 후 25%가 발생하고, 나머지는 고용 지속 조건에 따라 12개의 동등한 분기별 분할 지급으로 발생합니다.
89bio, Inc. (Nasdaq: ETNB), une entreprise bio-pharmaceutique en phase clinique spécialisée dans les maladies hépatiques et cardiométaboliques, a annoncé une subvention d'incitation approuvée par son Comité de Rémunération. La subvention comprend des options d'achat d'actions non qualifiées pour l'achat de 15 000 actions de l'action ordinaire de l'entreprise, attribuées à un nouvel employé le 13 septembre 2024.
La subvention, accordée dans le cadre du Plan d'Incitation 2023 de l'entreprise, est conforme à la règle de cotation 5635(c)(4) de Nasdaq. Le prix d'exercice est égal au prix de clôture des actions ordinaires de 89bio à la date de la subvention. Les options perceront sur quatre ans, avec 25 % perçus après un an et le reste perçu en 12 paiements trimestriels égaux, sous condition de maintien de l'emploi.
89bio, Inc. (Nasdaq: ETNB), ein biopharmazeutisches Unternehmen in klinischer Phase, das sich auf Leber- und kardiometabolische Krankheiten konzentriert, hat einen Anreizzuschuss angekündigt, der von seinem Vergütungsausschuss genehmigt wurde. Der Zuschuss umfasst nicht qualifizierte Aktienoptionen zum Kauf von 15.000 Aktien des Stammkapitals des Unternehmens, die einem neuen Mitarbeiter am 13. September 2024 gewährt werden.
Der Zuschuss, der im Rahmen des 2023 Anreizplans des Unternehmens erfolgt, entspricht der Nasdaq-Listing-Regel 5635(c)(4). Der Ausübungspreis entspricht dem Schlusskurs der Stammaktien von 89bio am Zuteilungstag. Die Optionen werden über vier Jahre fällig, wobei 25% nach einem Jahr und der Rest in 12 gleichmäßigen vierteljährlichen Raten fällig wird, abhängig von der Fortsetzung der Anstellung.
- Attracting new talent with stock options aligns employee interests with company growth
- Compliance with Nasdaq listing rules demonstrates good corporate governance
- Potential dilution of existing shareholders' equity due to new stock options
SAN FRANCISCO, Sept. 19, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the Compensation Committee of the Company’s Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 15,000 shares of the Company’s common stock to one new employee (the “Inducement Grant”) on September 13, 2024 (the “Grant Date”). The Inducement Grant has been granted pursuant to the Company’s 2023 Inducement Plan (the “Plan”). The Inducement Grant was granted as an inducement material to the individual entering into employment with 89bio in accordance with Nasdaq Listing Rule 5635(c)(4).
The Inducement Grant has an exercise price per share that is equal to the closing price of 89bio’s common stock on the Grant Date. The Inducement Grant will vest over a four-year period, with
About 89bio
89bio is a clinical-stage biopharmaceutical company dedicated to the development of best-in-class therapies for patients with liver and cardiometabolic diseases who lack optimal treatment options. The company is in Phase 3 studies for its lead candidate, pegozafermin, for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and severe hypertriglyceridemia (SHTG). Pegozafermin is a specifically engineered, potentially best-in-class fibroblast growth factor 21 (FGF21) analog with unique glycoPEGylated technology that optimizes biological activity through an extended half-life. The company is headquartered in San Francisco. For more information, visit www.89bio.com or follow the company on LinkedIn.
Investor Contact:
Annie Chang
89bio, Inc.
investors@89bio.com
PJ Kelleher
LifeSci Advisors, LLC
+1-617-430-7579
pkelleher@lifesciadvisors.com
Media Contact:
Sheryl Seapy
Real Chemistry
sseapy@realchemistry.com
FAQ
How many shares of 89bio (ETNB) stock were granted in the inducement grant?
What is the vesting schedule for the 89bio (ETNB) inducement grant?
When was the 89bio (ETNB) inducement grant approved?
What is the exercise price for the 89bio (ETNB) stock options granted?
